Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Another Sea Change In Myeloma Promised By New Therapies, Combos

Executive Summary

Darzalex made a splash with impressive Phase III data in relapsed multiple myeloma at the EHA and ASCO meetings, but a range of other drugs are on the way, including a next-generation CD38 inhibitor from Sanofi, checkpoint inhibitors and Roche's BCL-2 Venclexta.


Related Content

Multiple Myeloma Would Make Good Guinea Pig For Oncology Cost Control
Takeda's Ninlaro Back In European Myeloma Race After CHMP Turnaround
Janssen Oncology Strategy: Take A Holistic Approach To R&D
CASTOR Propels J&J's Anti-CD38 Darzalex To Prime Position In Myeloma
Darzalex March Continues with EU Approval
Opinions Split On Newly Approved Myeloma Therapies At ASH


Related Companies